Results 61 to 70 of about 87,437 (368)
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia [PDF]
, 2011 Suppression of apoptosis by TP53 mutation contributes to resistance of acute myeloid leukemia (AML) to conventional cytotoxic treatment. Using differentiation to induce irreversible cell cycle exit in AML cells could be a p53-independent treatment ...
Anjali Advani +15 more
core +2 more sources
Effects of immunoregulatory drugs on human peripheral blood T lymphocytes function in vitro [PDF]
Archive of Oncology, 2002 BACKGROUND: The purpose of the study was to evaluate the mode of action of different immunoregulatory drugs in lymphocyte proliferation and activation METHODS: The drugs studied were prednisolone (PRED), cyclosporin A (CsA) the recombination of PRED and ...
Hatzistilianou Marija +6 more
doaj +1 more source
Clinical Cancer Research, 2020 Purpose: Cytarabine, 100–200 mg/mE+2/day, is commonly used in induction therapy of acute myelogenous leukemia (AML). Whether a higher dose of cytarabine would be more effective is unknown. Also, there is controversy whether high-dose cytarabine is better
Hui Wei +20 more
semanticscholar +1 more source
Daunorubicin and Cytarabine (Vyxeos)
Canadian Journal of Health Technologies, 2021 CADTH recommends that Vyxeos should be reimbursed by public drug plans for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) if certain conditions are met. Vyxeos should only be reimbursed if the induction cycles are administered in an inpatient ...
openaire +3 more sources
Treatment of central nervous system lymphoma — literature review and own experiences
Онкогематология, 2014 Central nervous system (CNS) involvement in advanced non-Hodgkin’s lymphoma (NHL) occurs in 5–29 % of cases. Primary CNS lymphoma (PLCNS) significantly less revealed: 1–2 % of lymphoma cases and 5 % of all malignant CNS diseases.
S. V. Minenko +11 more
doaj +3 more sources
Journal of Lipid Research, 2023 Chemotherapy-induced cachexia causes severe metabolic abnormalities independently of cancer and reduces the therapeutic efficacy of chemotherapy. The underlying mechanism of chemotherapy-induced cachexia remains unclear.
Mi-Rae Park +9 more
doaj +1 more source
Aging, 2020 Targeting autophagy holds promise to enhance chemosensitivity in acute myeloid leukemia (AML). MicroRNA-143 (miR-143) has been found to suppress autophagy, however, it is not clear whether miR-143 augments cytarabine cytotoxicity in AML.
Hao Zhang +5 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad +17 more
wiley +1 more source
Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets
Marine Drugs, 2019 The role of the marine environment in the development of anticancer drugs has been widely reviewed, particularly in recent years. However, the innovation in terms of clinical benefits has not been duly emphasized, although there are important ...
Renato B. Pereira +7 more
doaj +1 more source
Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies [PDF]
, 2019 In cancer research, it remains challenging to functionally validate putative novel oncogenic drivers and to establish relevant preclinical models for evaluation of novel therapeutic strategies.
Berx, Geert +16 more
core +2 more sources